Cargando…

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome

BACKGROUND: Abciximab reduces major adverse cardiac events in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI). Standard protocol is intravenous abciximab bolus during PCI plus abciximab infusion for 12–18 h post pPCI. Intracoronary (IC) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shakoor, Muhammad Tariq, Ayub, Samia, Dhakam, Sajid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801446/ https://www.ncbi.nlm.nih.gov/pubmed/29450173 http://dx.doi.org/10.1016/j.ijchv.2014.03.007

Ejemplares similares

Intracoronary versus Intravenous Administration of Abciximab in Patients with Acute Coronary Syndrome: A Meta-Analysis
por: Wang, Jie-Ning, et al.
Publicado: (2013)

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008)

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
por: Vergara-Jimenez, Jennifer, et al.
Publicado: (2010)

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction
por: Namazi, Mohammad Hasan, et al.
Publicado: (2013)

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
por: Gu, Youlan L, et al.
Publicado: (2009)

Effects of intracoronary antithrombotics on ventricular function: A comparison of tenecteplase versus abciximab during primary percutaneous intervention in myocardial infarction
por: Morales-Ponce, Francisco J., et al.
Publicado: (2021)

Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab
por: Moon, Su-Jin, et al.
Publicado: (2008)

Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention
por: Shoukat, Sana, et al.
Publicado: (2010)

Abciximab: a reappraisal of its use in coronary care
por: Valgimigli, Marco, et al.
Publicado: (2008)

Editorial: Intracoronary Imaging Guidance for Percutaneous Coronary Interventions
por: Caiazzo, Gianluca, et al.
Publicado: (2022)

Efficacy of Combination Treatment with Intracoronary Abciximab and Aspiration Thrombectomy on Myocardial Perfusion in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Stenting
por: Ahn, Sung Gyun, et al.
Publicado: (2014)

Intracoronary Lithoplasty in Percutaneous Treatment of Challenging Calcified Coronary Lesions
por: Marchese, Alfredo, et al.
Publicado: (2020)

Intracoronary physiology-guided percutaneous coronary intervention in patients with diabetes
por: Scarsini, Roberto, et al.
Publicado: (2023)

Intracoronary administration of tirofiban during percutaneous coronary intervention facilitates patients with acute coronary syndrome
por: Jia, Helei, et al.
Publicado: (2017)

Usefulness of Intracoronary Epinephrine in Severe Hypotension during Percutaneous Coronary Interventions
por: Choi, Jin Hee, et al.
Publicado: (2013)

Intracoronary Lithotripsy in Percutaneous Treatment of Calcific Left Main Coronary Stenoses
por: Salazar, Carlos H., et al.
Publicado: (2019)

Intracoronary injection of nitroglycerine can prevent unnecessary percutaneous coronary intervention
por: Nasiri-Partovi, Amirhossein, et al.
Publicado: (2022)

Abciximab: Abciximab-induced alveolar haemorrhage: case report
Publicado: (2021)

Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis
por: Wu, Yihua, et al.
Publicado: (2011)

Migration of fully deployed stent after intracoronary glyceryl trinitrate administration: An unusual percutaneous coronary intervention complication
por: Celik, Murat, et al.
Publicado: (2013)

Intracoronary application of nicorandil regulates the inflammatory response induced by percutaneous coronary intervention
por: Hu, Keqing, et al.
Publicado: (2020)

Eptifibatide Bolus Dose During Elective Percutaneous Coronary Intervention
por: Doustkami, Hossein, et al.
Publicado: (2018)

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention
por: Marian, Moazez J., et al.
Publicado: (2017)

High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI – The Tamip Study
por: Balghith, Mohammed A.
Publicado: (2012)

Spontaneous Bleeding from Internal Pudendal Artery associated with Abciximab after Primary Percutaneous Coronary Intervention: Successful Treatment with Percutaneous Gel-Foam Embolization
por: Lee, Seung-Eun, et al.
Publicado: (2016)

Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Xu, Xingli, et al.
Publicado: (2020)

COVID CORONARY: INTRACORONARY THROMBOLYTICS TO THE RESCUE
por: Randall, Morgan, et al.
Publicado: (2022)

Anti-inflammatory Effect of Abciximab-Coated Stent in a Porcine Coronary Restenosis Model
por: Hong, Young Joon, et al.
Publicado: (2007)

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
por: Park, Soonyoung, et al.
Publicado: (2013)

Effect of Intravenous Abciximab on Coronary Flow Improvement After Re-vascularization in Primary Coronary Intervention and Short Term Impact
por: Rgeeb, Ahmed N., et al.
Publicado: (2020)

Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention
por: Muraca, Iacopo, et al.
Publicado: (2023)

Impact of Intracoronary Imaging‐Guided Percutaneous Coronary Intervention on Procedural Outcomes Among Complex Patient Groups
por: Mohamed, Mohamed O., et al.
Publicado: (2022)

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio
por: Voisard, Rainer, et al.
Publicado: (2006)

Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials
por: Tang, Xiuying, et al.
Publicado: (2015)

Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry)
por: Dziewierz, Artur, et al.
Publicado: (2012)

Multivessel versus Culprit-Only Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome
por: Pustjens, Tobias F. S., et al.
Publicado: (2022)

A case of successful primary coronary intervention for the total occlusion of left main stem with the aid of abciximab.
por: Jeong, M. H., et al.
Publicado: (2001)

Utility of Optical Coherence Tomography to Assess a Hazy Intracoronary Image after Percutaneous Coronary Intervention
por: Carrizo, Sebastian, et al.
Publicado: (2013)

Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study
por: Aksu, Tolga, et al.
Publicado: (2015)

Survivals of Angiography-Guided Percutaneous Coronary Intervention and Proportion of Intracoronary Imaging at Population Level: The Imaging Paradox
por: Ng, Andrew Kei-Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jgpqmar5agj4f5698loe75p411